PGR and breast cancer: Luminal A and B BC, characterized by estrogen receptor (ER) and/or progesterone receptor (PR) positivity, face challenges in endocrine therapy due to acquired resistance, frequently driven by PI3K/AKT/mTOR pathway activation.